The pursuit of HDL-C as a biomarker for CETP inhibition resulted in significant financial loss and lives lost during clinical trials. — Whalespan
The pursuit of HDL-C as a biomarker for CETP inhibition resulted in significant financial loss and lives lost during clinical trials.
⚠ High risk
We can't find evidence that holds up here. Proponents are reasoning from mechanism or analogy rather than direct human data, and the most credible skeptics raise objections we can't dismiss.
✕NOTSUPPORTED
⚠
High-risk intervention — consult a physician before acting.Drug-drug interactions, dose-dependence, and screening contraindications apply.
“and failing to understand the mechanism of that 15 years and I don't know how many billions of dollars but it's probably approaching 10 billion if not more dollars were wasted and tragically by the way it should be noted some lives were lost right”
“we lost our way we as the field meaning like meaning I'm just observing the field but the field lost its way in this drug based on the wrong biomarker we were using hdlc as a biomarker because we didn't have a better biomarker for c-tep inhibition”